Upgrade to SI Premium - Free Trial

Incyte (INCY) Reiterated at Market Perform by BMO Capital, 2022 All About Opzelura Revenues

February 8, 2022 8:15 AM
BMO Capital analyst Evan David Seigerman reiterated a Market Perform rating and $75.00 price target on Incyte (NASDAQ: INCY) following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Trader Talk

Next Articles